PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Keytruda Filed in Japan for Urothelial Cancer: MSD
April 28, 2017
- Harvoni Filed for Genotype 2 Hepatitis C: Gilead Japan
April 28, 2017
- Takeda Joins Hands with Harrington Institute on Rare Disease Therapeutics
April 28, 2017
- Pfizer Files Japan NDA for ALL Treatment
April 28, 2017
- Certican Filed in Japan for Liver Transplant Rejection: Novartis
April 28, 2017
- Daiichi Sankyo to More than Triple ADC Production Capacities by 2021
April 28, 2017
- Kyowa Kirin Submits Regpara Successor in Japan
April 28, 2017
- Astellas Looking to Xtandi Growth Outside US: President
April 28, 2017
- Astellas Sales Dip 4.4% on Forex Moves, Japan Biz Dented by Price Cuts
April 28, 2017
- Otsuka, Akebia Expand Licensing Pact for Anemia Med Vadadustat
April 27, 2017
- Nippon Kayaku to Codevelop Celltrion’s Rituxan Biosimilar
April 27, 2017
- Janssen Files Japan NDA for Multidrug-Resistant TB Drug
April 26, 2017
- Humira Filed for Pustular Psoriasis in Japan: AbbVie
April 26, 2017
- Mundipharma Japan Chief Voices Eagerness on Rare Cancer Therapies
April 25, 2017
- Kissei Ditches Dry Eye Med KCT-0809
April 25, 2017
- Lumicef PIII Kicks In for Axial Spondyloarthritis: Kyowa Kirin
April 25, 2017
- Drug Costs Can’t Be Curbed with Uniform Pricing of Gx, LLPs: Teva Takeda CEO
April 24, 2017
- With Upsher-Smith Deal Inked, Sawai Looks to Make US Market Its Second Biz Pillar
April 24, 2017
- Janssen’s Sirukumab Exhibits Significant Improvements in Primary Endpoints in Japanese PIII Studies
April 24, 2017
- Benralizumab Demonstrates Favorable Results in Subgroup Analysis of Japanese Bronchial Asthma Patients: AZ
April 24, 2017
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…